MedTrace Logo

Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms

NCT07626021 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-06-04

No results posted yet for this study

Summary

Myeloproliferative neoplasms are chronic blood cancers in which the bone marrow produces too many blood cells. Patients with Philadelphia chromosome-negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may need treatment to reduce high blood cell counts, relieve disease-related symptoms, and lower the risk of complications. However, currently available cytoreductive treatments may be ineffective, poorly tolerated, or inconvenient for some patients.

Selinexor is an oral selective inhibitor of nuclear export that has shown antitumor activity in several hematologic malignancies. This study will evaluate the effectiveness and safety of selinexor used alone as cytoreductive treatment in patients with Philadelphia chromosome-negative myeloproliferative neoplasms who have an indication for cytoreductive therapy.

This is a prospective, single-arm, open-label phase II study conducted at a single center. Eligible participants will receive oral selinexor, with dose adjustments based on tolerability and blood cell counts. Participants will be followed for treatment response, symptom improvement, and side effects for up to 6 months. The results of this study may help determine whether selinexor could provide a potential treatment option for patients with Philadelphia chromosome-negative myeloproliferative neoplasms who have limited cytoreductive therapy choices.

Conditions

  • Myeloproliferative Neoplasms

Interventions

DRUG

Selinexor

Selinexor will be administered orally at an initial dose of 40 mg once weekly. Treatment may be continued for up to 3 months, with a planned total follow-up period of 6 months. Dose escalation to 60 mg or 80 mg once weekly is permitted in participants without significant hematologic or non-hematologic toxicity, according to the investigator's judgment. Dose interruption and dose reduction are allowed based on safety and tolerability. In the event of grade 3 or higher hematologic toxicity or clinically significant non-hematologic toxicity, selinexor will be temporarily withheld and resumed at a reduced dose after recovery. Treatment will be permanently discontinued if unacceptable toxicity persists despite dose modification.

Sponsors & Collaborators

  • Zhongshan Hospital (Xiamen), Fudan University

    lead OTHER

Principal Investigators

  • Zheng Wei · Zhongshan Hospital (Xiamen), Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2026-08-31
Completion
2026-08-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07626021 on ClinicalTrials.gov